A. Oliver Sartor, MD, discusses the design for an observational study of disease characteristics and outcome of patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA after receiving radium-223.
A. Oliver Sartor, MD, professor of Medicine, medical director of Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research at Tulane University, discusses the design for an observational study (NCT02141438) of disease characteristics and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA after receiving radium-223.
According to the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the outcome was that grade 3/4 hematologic adverse events after treatment with radium-223 were low and treatment with subsequent 177Lu-PSMA seems feasible.
Sartor says that there is a fair group of investigators that have been involved with looking at longer-term follow-up of the use of radium-223 in these patients. There is an extensive database that investigators can use to understand what the ultimate outcomes may be for patients with mCRPC who were treated in selected center involved with a prospective registry.
In addition to outcomes such as secondary cancers and survival, the investigators also collected data for this study in regard to subsequent therapies, according to Sartor. They don’t understand yet if the subsequent therapies were effective or not, but they did look at whether they were used and for how long to get durations of survival. He says the substrate for the study was patients who were on radium-223 at selected practices participating in a prospective registry and were also reporting on subsequent use of 177Lu-PSMA in patients.